This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $503.31, marking a -1.36% move from the previous day.
2 Great Value Stocks to Buy in April and Hold for Years
by Benjamin Rains
After the bullish first quarter, we dig into two highly-ranked Zacks stocks--Humana (HUM) and O-I Glass, Inc. (OI)--that offer investors great value, alongside the ability to thrive in all types of economic conditions.
Here's Why Investors Should Hold Ensign Group (ENSG) Stock Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, continuous pursuit of acquisitions and commendable financial position.
Is Humana (HUM) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is What to Know Beyond Why Humana Inc. (HUM) is a Trending Stock
by Zacks Equity Research
Humana (HUM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $506.99, moving +0.91% from the previous trading session.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $491.35, marking a -1.4% move from the previous day.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare are part of the Zacks Industry Outlook article.
Humana (HUM) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $495.55, marking a +0.24% move from the previous day.
5 HMO Stocks to Watch Despite Elevated Tech Costs, Nursing Shortage
by Debasmita Chatterjee
Improved premiums cropping from a solid customer base might aid the Medical-HMO industry. However, an escalating expense level and an acute shortage of nurses are roadblocks. Stocks like UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Humana Inc. (HUM) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Humana (HUM). This makes it worthwhile to examine what the stock has in store.
Humana (HUM) Rises 9.7% in a Year: More Room for Growth?
by Zacks Equity Research
Humana's (HUM) individual Medicare Advantage membership growth is likely to boost premium income.
Should Value Investors Buy Humana (HUM) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $481.97, moving -0.11% from the previous trading session.
The Zacks Analyst Blog Highlights UnitedHealth, Elevance Health, Humana and Centene
by Zacks Equity Research
UnitedHealth, Elevance Health, Humana and Centene are included in this Analyst Blog.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $489.31, marking a -1.36% move from the previous day.
Acadia Healthcare (ACHC) to Build Behavioral Health Unit in Mesa
by Zacks Equity Research
Acadia Healthcare (ACHC) begins the construction of its Mesa-based behavioral health hospital to address the inadequacy of behavioral healthcare resources in Arizona.
Will Biden's Tax Hike Plan Extend Medicare's Life to 2050?
by Kaibalya Pravo Dey
U.S. President Joe Biden's proposal is also likely to enhance Medicare's ability to negotiate prices for drugs.
Humana Inc. (HUM) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Humana (HUM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Humana (HUM) Ties Up To Offer Value-Based Care to MA Members
by Zacks Equity Research
Humana (HUM) inks a 10-year collaboration with Aledade to ensure continued value-based primary care to its Medicare Advantage members from Aledade-backed physicians.
Humana (HUM) Up 1.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $495.76, moving -0.08% from the previous trading session.
Why Humana (HUM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Humana (HUM), CD&R Backed Gentiva to Buy Assets From ProMedica
by Zacks Equity Research
The acquisition is expected to boost Humana (HUM) and CD&R backed Gentiva's reach to over 500 locations.
Humana (HUM) Exits Business Line to Focus More on Core Units
by Zacks Equity Research
Humana (HUM) will depart from the Employer Group Commercial Medical Products business so that it can invest more funds to grow its core Insurance business lines.